Tracking Susceptibility and Reducing Resistance - Fluoroquinolones at the Forefront in the Fight Against Bacterial Pathogens

29 March, 2018

References

1. Conte JE Jr, Golden JA, McIver M, Little E, Zurlinden E. Intrapulmonary pharmacodynamics of highdose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. Int J Antimicrob Agents 2007; 30: 422-7.
2. Cazzola M, Matera MG, Donnarumma G, Tufano MA, Sanduzzi A, Marchetti F, Blasi F. Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. Chest 2005; 128: 2093-8.
3. Homma T, Hori T, Sugimori G, Yamano Y. Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 51: 3810-5.
4. DeFife R, Scheetz MH, Feinglass JM, Postelnick MJ, Scarsi KK. Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. Antimicrob Agents Chemother 2009; 53: 1074-9.
5. Yokota S, Ohkoshi Y, Fujii N. Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates. Diagn Microbiol Infect Dis 2009; 65: 76-80.
6. Schafer J, Hovde LB, Simonson D, Rotschafer JC. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Diagn Microbiol Infect Dis 2008 60: 155-61.
7. Cantón R, Lode H, Graninger W, Milkovich G. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. Int J Antimicrob Agents 2006; 28(Suppl 2): S115-27.
8. Noguera O, Rodriguez JC, Lopez JM, Ruiz M, Royo G. Resistant mutant prevention concentration of fluoroquinolones in clinical isolates of extended spectrum beta-lactamase (ESBL) producing and non-producing strains of Escherichia coli. Rev Esp Quimioter 2009; 22: 30-3.
9. Blasi F, Farrell DJ, Dubreuil L. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003-2004). Diagn Microbiol Infect Dis 2009; 63: 302-8.
10. de la Pedrosa EG, Morosini MI, van der Linden M, Ruiz-Garbajosa P, Galan JC, Baquero F, Reinert RR, Canton R. Polyclonal population structure of Streptococcus pneumoniae isolates in Spain carrying mef and mef plus erm (B). Antimicrob Agents Chemother 2008; 52: 1964-9.
11. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 2009; 15: 1260-4.
12. Chen J, Liu L, Wang G, Chen Y, Luo Z, Huang Y, Fu Z, Yang Y, Liu E. Correlation between usage of macrolide antibiotic and resistance of Streptococcus pneumoniae clinic isolates from chongqing children’s hospital. Pediatr Pulmonol 2009; 44: 917-21.
13. de la Pedrosa EG, Morosini MI, van der Linden M, Ruiz-Garbajosa P, Galan JC, Baquero F, Reinert RR, Canton R. Polyclonal population structure of Streptococcus pneumoniae isolates in Spain carrying mef and mef plus erm (B). Antimicrob Agents Chemother 2008; 52: 1964-9.
14. Jacobs E, Dalhoff A, Korfmann G. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study). Int J Antimicrob Agents 2009; 33: 52-7.
15. Ho PL, Cheng VC, Chow KH. Decreasing prevalence of levofloxacin-resistant Streptococcus pneumoniae in Hong Kong, 2001 to 2007. J Antimicrob Chemother 2009; 63: 836-8.
16. Felmingham D, Canton R, Jenkins SG. Regional trends in β-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007; 55: 111-8.
17. Vardakas KZ, Siempos II, Grammatikos A, Athanassa Z, Korbila IP, Falagas ME. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008; 179: 1269-77.
18. Sahm DF, Brown NP, CheungYee Y, Evangelista AT. Stratified analysis of multidrug-resistant Escherichia coli in US health care institutions. Postgrad Med 2008; 120(3 Suppl 1): 16-24.
19. Rozen DE, McGee L, Levin BR, Klugman KP. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 51: 412-6.
20. Lister PD. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacinresistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002; 44: 43-9.
21. Lister PD. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae. Postgrad Med 2008; 120 (3 Suppl 1): 46-52.
22. De Vecchi E, Nicola L, Ossola F, Drago L. In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations. J Antimicrob Chemother 2009; 63: 721-7.
23. Sierra JM, Cabeza JG, Ruiz Chaler M, Montero T, Hernandez J, Mensa J, Llagostera M, Vila J. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clin Microbiol Infect 2005; 11: 750-8.